Federated Hermes’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-6,697
Closed -$11.1K 2260
2022
Q4
$11.1K Buy
+6,697
New +$18.8K ﹤0.01% 1859

Other funds holding STLN

Federated Hermes's STLN Position: Q1 2023 in Review

Federated Hermes sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2023, closing a stake of 6,697 shares — an estimated $11.1K sold.

Federated Hermes first reported a position in STLN in Q4 2022 and held it in 1 quarter. The position peaked at $11.1K in Q4 2022. 39 funds tracked by Wall St. Rank hold STLN as of Q1 2023.

  • Federated Hermes reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 6,697 Starling Oncology Institute, Inc. Common Stock shares in Q1 2023, an estimated $11.1K.
  • Federated Hermes first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Federated Hermes's Starling Oncology Institute, Inc. Common Stock position peaked at $11.1K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.